Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.
View/ Open
Date
2014-08-01ICR Author
Author
Tubio, JMC
Li, Y
Ju, YS
Martincorena, I
Cooke, SL
Tojo, M
Gundem, G
Pipinikas, CP
Zamora, J
Raine, K
Menzies, A
Roman-Garcia, P
Fullam, A
Gerstung, M
Shlien, A
Tarpey, PS
Papaemmanuil, E
Knappskog, S
Van Loo, P
Ramakrishna, M
Davies, HR
Marshall, J
Wedge, DC
Teague, JW
Butler, AP
Nik-Zainal, S
Alexandrov, L
Behjati, S
Yates, LR
Bolli, N
Mudie, L
Hardy, C
Martin, S
McLaren, S
O'Meara, S
Anderson, E
Maddison, M
Gamble, S
Foster, C
Warren, AY
Whitaker, H
Brewer, D
Eeles, R
Cooper, C
Neal, D
Lynch, AG
Visakorpi, T
Isaacs, WB
Veer, LV
Caldas, C
Desmedt, C
Sotiriou, C
Aparicio, S
Foekens, JA
Eyfjörd, JE
Lakhani, SR
Thomas, G
Myklebost, O
Span, PN
Børresen-Dale, A-L
Richardson, AL
Van de Vijver, M
Vincent-Salomon, A
Van den Eynden, GG
Flanagan, AM
Futreal, PA
Janes, SM
Bova, GS
Stratton, MR
McDermott, U
Campbell, PJ
ICGC Breast Cancer Group,
ICGC Bone Cancer Group,
ICGC Prostate Cancer Group,
Type
Journal Article
Metadata
Show full item recordAbstract
Long interspersed nuclear element-1 (L1) retrotransposons are mobile repetitive elements that are abundant in the human genome. L1 elements propagate through RNA intermediates. In the germ line, neighboring, nonrepetitive sequences are occasionally mobilized by the L1 machinery, a process called 3' transduction. Because 3' transductions are potentially mutagenic, we explored the extent to which they occur somatically during tumorigenesis. Studying cancer genomes from 244 patients, we found that tumors from 53% of the patients had somatic retrotranspositions, of which 24% were 3' transductions. Fingerprinting of donor L1s revealed that a handful of source L1 elements in a tumor can spawn from tens to hundreds of 3' transductions, which can themselves seed further retrotranspositions. The activity of individual L1 elements fluctuated during tumor evolution and correlated with L1 promoter hypomethylation. The 3' transductions disseminated genes, exons, and regulatory elements to new locations, most often to heterochromatic regions of the genome.
Collections
Subject
ICGC Breast Cancer Group
ICGC Bone Cancer Group
ICGC Prostate Cancer Group
Chromatin
Humans
Neoplasms
Translocation, Genetic
DNA Transposable Elements
Transduction, Genetic
Mutagenesis, Insertional
Long Interspersed Nucleotide Elements
Genome, Human
Exons
Carcinogenesis
Research team
Oncogenetics
Language
eng
License start date
2014-08
Citation
Science (New York, N.Y.), 2014, 345 (6196), pp. 1251343 - ?
Publisher
AMER ASSOC ADVANCEMENT SCIENCE
Related items
Showing items related by title, author, creator and subject.
-
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
Leung, SCY; Nielsen, TO; Zabaglo, LA; Arun, I; Badve, SS; et al. (2019-08)Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The ... -
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
Casali, PG; Zalcberg, J; Le Cesne, A; Reichardt, P; Blay, J-Y; et al. (2017-05)Purpose To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). ... -
Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer.
Painter, JN; O'Mara, TA; Marquart, L; Webb, PM; Attia, J; et al. (AMER ASSOC CANCER RESEARCH, 2016-11-01)BACKGROUND: The strongest known risk factor for endometrial cancer is obesity. To determine whether SNPs associated with increased body mass index (BMI) or waist-hip ratio (WHR) are associated with endometrial cancer risk, ...